Background Most economic evaluations of smoking cessation interventions have used cohort state-transition models. Discrete event simulations (DESs) have been proposed as a superior approach. Objective We developed a state-transition model and a DES using the discretely integrated condition event (DICE) framework and compared the cost-effectiveness results. We performed scenario analysis using the DES to explore the impact of alternative assumptions. Methods The models estimated the costs and quality-adjusted life years (QALYs) for the intervention and comparator from the perspective of the UK National Health Service and Personal Social Services over a lifetime horizon. The models considered five comorbidities: chronic obstructive pulmonary disease, myocardial infarction, coronary heart disease, stroke and lung cancer. The statetransition model used prevalence data, and the DES used incidence. The costs and utility inputs were the same between two models and consistent with those used in previous analyses for the National Institute for Health and Care Excellence. Results In the state-transition model, the intervention produced an additional 0.16 QALYs at a cost of £540, leading to an incremental cost-effectiveness ratio (ICER) of £3438. The comparable DES scenario produced an ICER of £5577. The ICER for the DES increased to £18,354 when long-term relapse was included. Conclusions The model structures themselves did not influence smoking cessation cost-effectiveness results, but long-term assumptions did. When there is variation in longterm predictions between interventions, economic models need a structure that can reflect this.
Introduction
Economic models may use different structures, and there is much discussion and guidance in the literature on how to choose the model structure [1] [2] [3] [4] . The choice of model structure is viewed as important in any disease or health area, including in smoking cessation. Discrete event simulation (DES) models are noted to offer advantages over state-transition models in terms of incorporating history, avoiding limitations of discrete time intervals and facilitating a flexible framework [5] . Commonly cited disadvantages of DESs include the need for additional data, complexity of programming, the need for specialist software, and long run-times.
The discretely integrated condition event (DICE) simulation framework has been developed to allow modellers to build flexible models in Microsoft Excel [6] . DICE can operate at the individual level or cohort level, and be driven by states (for state-transition modelling) or by events (for DESs). For modellers developing DESs, DICE removes the need to use specialist software and simplifies the coding process. The use of DICE has previously been explored in DES modelling, where it was noted that the DICE framework produced results almost identical to (within 1% of) the original ones [7] .
Smoking is a substantial public health burden in the UK [8] , leading to premature death, excess morbidity, and incurring a high cost to the National Health Service (NHS). With the NHS spending upwards of £36 million on smoking cessation in England alone in April-September 2016 [9] , it is important to understand how cost-effective smoking cessation interventions are. In 2013, Getsios et al. reported that models which consider only one smoking cessation attempt lead to biased estimates of cost-effectiveness, and suggested that DES provides a framework for modelling multiple quit attempts in smoking cessation [10] . The majority of economic models in smoking cessation to date have been cohort-level state-transition (Markov) or decision tree models [11, 12] . Indeed, the economic models used in the smoking cessation guidelines produced by the National Institute for Health and Care Excellence (NICE) are all cohort-level models [13] [14] [15] [16] [17] [18] [19] . There therefore remains a question as to whether DES models would generate the same results as state-transition models in smoking cessation. A further challenge exists regarding the feasibility of developing DES models in smoking cessation, in terms of data availability and complexity of coding. The purpose of our study was twofold: (1) to explore the feasibility of developing a smoking cessation DES model using DICE; (2) to compare the results of a cohort-level state-transition and DES model in smoking cessation.
Methods

Model Settings
We developed a cohort-level state-transition and a DES model to assess the cost-effectiveness of one intervention versus no treatment. The perspective of the analysis was the UK NHS and Personal Social Services (PSS), in accordance with the NICE reference case [20] . The discount rate for costs and benefits was 3.5% annually [20] . As far as possible, we kept all inputs the same between the models [20] . The intervention was a patch plus nasal spray, on which 27% of people had stopped smoking at 12 months [21] , and the intervention cost £763.74 [22] . No treatment was associated with a background net cessation rate of 2% annually, with no cost [19] . This net rate was also applied annually to people who had not quit on the intervention. The state-transition model used an annual cycle. Both models considered a lifetime horizon to incorporate the long-term health effects of smoking. We considered a cohort of people aged 16 years old, where 50% were male and 50% were female.
Comorbidities
Both models considered five smoking-related comorbidities: chronic obstructive pulmonary disease (COPD), coronary heart disease (CHD), myocardial infarction (MI), stroke and lung cancer. The utilities and costs associated with the comorbidities were based on those used in previous NICE smoking cessation models [13] [14] [15] [16] [17] [18] [19] , updated with additional searches, are the same in the two models, and are shown in Table 1 . The state-transition model, like previous NICE smoking cessation models [23] , uses prevalence data to model the proportion of the population with each comorbidity. In contrast, the DES considers patients developing a disease and so more naturally uses incidence data. This meant we could not use the same data as the state-transition model, and furthermore, we could not obtain equivalent data from the same sources. Sources of incidence and prevalence data for each of the comorbidities are shown in Table 1 .
Utility Values
Both models allowed utility to differ by smoker status and by presence of comorbidities. Vogl et al. reported utilities for smokers and non-smokers by age, gender and smoker status [24] . The state-transition model assumed a constant utility for smokers (0.8486), calculated by subtracting the average disutility of light, moderate and heavy smokers from the utility for a never smoker, and a constant utility for former smokers (0.8669), calculated by subtracting the disutility of ex-occasional and ex-regular smokers from the utility for a never smoker. The state-transition model uses utility decrements for each comorbidity, calculated as the difference between the utility for the health state and the utility of the comorbidity in Table 1 . The DES uses the same source, and has the option to use the same data as the state-transition model or to vary utility by age and gender. In this scenario, the model applies utility data for moderate smokers for smokers and for ex-regular smokers for former smokers, and incorporates age by including an event for utility change which occurs when a person crosses an age band. Vogl et al. provide utility decrements by number of comorbidities: 0.0938 for one, 0.1811 for two, 0.2859 for three and 0.3354 for four or more [24] . The DES can count the number of comorbidities and use these data, or use the specific utility decrement for each comorbidity like the state-transition model.
Model Structures
State-Transition Model Structure
In the state-transition model, a cohort of people transition between three health states: smoker, former smoker and dead. The prevalence of each comorbidity and the probability of death varied by smoker status. The model structure is shown in Fig. 1 . The population prevalence of each comorbidity and relative risk for a smoker versus a former smoker were taken from various sources; the sources are shown in Table 1 . We combined the population prevalence, relative risk by smoker status, and proportion of smokers in the population to estimate age-and genderspecific prevalence by smoker status for each comorbidity, consistent with the approach taken in previous models [10, 23] . Ex-smokers are people who used to smoke cigarettes regularly (at least one cigarette daily), and never smokers are people who never smoked cigarettes regularly. The following equation shows how prevalence in the general population can be decomposed, where C is prevalence, P is the proportion within the population, RR is relative risk, general is general population, never is never smokers, former is former smokers and current is current smokers:
The equation can be rearranged to give the prevalence in the never smoker population, where the other components are known: Løkke et al. [57] Public Health England data set; assumed 12-to 15-year-olds had 0.1% prevalence (1.28%) [58] British Lung Foundation [59] CHD coronary heart disease, COPD chronic obstructive pulmonary disease, MI myocardial infarction, NICE National Institute for Health and Care Excellence, PSSRU Personal Social Services Research Unit a All costs inflated to 2014/15 using PSSRU [60] Smoking Cessation: A Comparison of Two Model Structures
Discrete Event Simulation (DES) Model Structure
The DES model simulates 5000 hypothetical people, and an individual pathway through the model is determined for each person. Whereas in a state-transition model, a proportion of people have each event (or move to a different state) in each time cycle, in a DES, each simulated person has each event at their own specific time. They then follow that sequence of events until they die and exit the model. The time at which each event happens depends on the person's characteristics, history and random numbers. Comparing random numbers against probabilities of events occurring ensures that the appropriate proportion of patients have each event at each time point.
The time to each comorbidity uses incidence data, which varies by smoker status. We used the same relative risks for smoker versus former smoker as the state-transition model, and incidence data from various sources ( Table 1) . Like the state-transition model, we combined the population incidence, relative risk by smoker status and proportion of smokers in the population to estimate incidence by smoker status for each comorbidity.
The model structure is shown in Fig. 2 . It has 11 events; apart from ''Start'' and ''End'' (mandatory events in DICE), there are ''QuitAttempt'', ''Failure'', ''Success'', ''Relapse'', ''UtilityChange'', ''MI'', ''CHD'', ''COPD'', ''Stroke'', ''LungCancer'' and ''Death''. The ongoing information is stored in conditions covering age, smoker status, comorbidity status, utility, event times and random numbers. Accumulator outputs are defined for life years, QALYs and costs (by category), and counters track the number of quit attempts and incidence of comorbidities. A description of the process in the DES model is provided in the Supplementary Appendix (see the electronic supplementary material).
Research has shown that relative risks of developing comorbidities decrease with time since cessation, so the DES allows this [25] . The equation to model this has previously been used in smoking DES models [10] and considers age and gender in addition to time since cessation. Utilising baseline characteristics and history is a known advantage of DES models over state-transition models, and this equation was not considered in the statetransition model (although it may be possible with multiple tunnel states). To use the equation in the DES, we needed to adjust background disease incidence to consider the time at which the former smokers in the population had quit smoking. We estimated this using longitudinal data on the proportion of cigarette smokers who had quit by age and gender [26] , combined with the proportion of smokers and non-smokers by age and gender [9] , using the same approach to that used for estimating prevalence and incidence in the general population. In this case, the relative risk for a former smoker is calculated as in the following equation, where c and g are comorbidity-specific parameters from Getsios et al. [10] (we used the MI parameters as a proxy for CHD): 
State-Transition Model Mortality
Mortality varied by smoker status, using relative risk data from two studies by Doll et al. [27, 28] . Mortality for former smokers was calculated by applying the relative risks for former and current smokers to the proportion of the UK population who are former and current smokers in a similar way to the equations for prevalence and using life tables from the Office for National Statistics (ONS). The relative risk for smokers was applied to the calculated former smoker mortality in the model.
DES Model Mortality
Smoking cessation models which consider disease incidence may link comorbidity presence to mortality [29] rather than linking smoker status to mortality as the statetransition model does. The DES has the flexibility to either link comorbidity presence or smoker status to mortality, but not both. We calculated the relative risk of death for each comorbidity by combining comorbidity prevalence data (used in the state-transition model) with the number of all-cause deaths and number of deaths from each comorbidity from ONS death registration data [30] , using the following equation:
RR comorbidity:no comorbidity ¼ number of deaths from comorbidity number of all cause deaths Ä prevalence of comorbidty
Long-Term Pathway
The base-case analysis considered only one smoking cessation attempt, but long-term effectiveness was explored in scenario analysis. The economic models for NICE guidelines consider only one smoking cessation attempt, and our primary aim was to understand whether using a DES in this scenario would lead to similar results. However, since the inclusion of multiple quit attempts has been highlighted as important [10] , we considered a scenario in the DES whereby people who have quit smoking may later relapse. We used the annual long-term relapse probabilities considered in a previous UK economic evaluation of smoking cessation interventions: 0.129 for [1 to \5 years post cessation, 0.0331 for C 5 to \10 years post cessation, and 0.00112 for [10 years post cessation [29] .
Scenarios Considered
We ran the state-transition model for the described settings. The flexibility of a DES allows multiple scenarios to be modelled with relative ease, and we considered several scenarios in the DES, as follows:
1. Mortality linked to smoker status; relative risk of comorbidities does not vary by time since cessation; utility data same as the state-transition model.
2. Same as scenario 1, except mortality linked to comorbidity. As we believe this scenario is more realistic, we consider this as the basis for scenarios 3-5. 3. Same as scenario 2, except relative risk of comorbidities varies by time since cessation. 4. Same as scenario 2, except varies utility by age and gender and uses utility decrements for number of comorbidities. 5. Same as scenario 2, except considering long-term relapse.
Scenarios 1 and 2 aim to match the state-transition model settings as closely as possible, while scenario 3 and 4 explore additional complexity facilitated by the DES, and scenario 5 aims to consider an additional element of smoking cessation that NICE has previously recognised as important [31, 32] but has not been formally explored in economic models for public health guidelines.
Results
In both models and in all scenarios, the intervention was associated with higher costs, more life years and more quality-adjusted life years (QALYs) than the comparator. This is because the intervention leads to fewer comorbidities and improves survival compared with no treatment, and so increases life years and QALYs. By reducing comorbidity occurrence, the intervention has some cost offsets, so the incremental cost is less than the initial intervention cost. Results for all scenarios are shown in Table 2 .
State-Transition Model
In the state-transition model, the incremental costs are £540 and the incremental QALYs are 0.16, leading to an incremental cost-effectiveness ratio (ICER) of £3438/ QALY. This is well below the £20,000-£30,000/QALY range generally considered cost-effective by NICE [20] . It therefore appears that the intervention is good value for money.
DES: Scenario 1
In the DES, when mortality is linked to smoker status, the incremental costs are £47 and the incremental QALYs are 0.12, yielding an ICER of £399/QALY. The total costs for intervention and comparator are much higher than in the state-transition model because people with costly comorbidities are not assumed to have any reduction in life expectancy, so accrue high costs.
DES: Scenario 2
In this scenario, the people who develop comorbidities die sooner than the people who do not, and so do not incur such high costs. This scenario could be considered the most comparable to the state-transition model, and indeed gives results that are more comparable to the state-transition model than those in scenario 1. The total costs and QALYs for intervention and comparator are lower than the statetransition model, but the incremental costs are relatively similar. The number of people developing comorbidities does differ from the state-transition model, as might reasonably be expected for different data sources. A breakdown of comorbidity costs is shown in Table 3 .
DES: Scenario 3
In the scenario where the relative risk of comorbidities varies by time since cessation, there are higher incremental QALYs and lower incremental costs, leading to a lower ICER than in scenario 2. This is because the benefit of quitting smoking increases over time, and the smokers who quit do so at a young age in the model. The underlying incidence has changed in this scenario as we have adjusted the background incidence in the population to account for time since quitting in the background population.
DES: Scenario 4
In the scenario where the number of, and not type of, comorbidity is linked to utility decrement, the total costs are unchanged and the QALYs increase in both arms. The incremental QALYs increase by 0.03, and so the ICER decreases by £1300 compared with scenario 2. Accounting for the relative frequency of each comorbidity, the average comorbidity decrement in the base case is 0.20, which is higher than the decrement of 0.09 from Vogl et al. [24] . When Vogl et al. is used, the average utility increases, and so there are more QALYs gained from the incremental survival with the intervention. The effect is not large because the QALYs gained from former smokers generally having higher utility than smokers are unchanged. This scenario indicates that this change does not make a large difference to the results.
DES: Scenario 5
When long-term relapse is added in, the incremental costs remain relatively unchanged, but the incremental QALYs decrease substantially, leading to a much higher ICER of £18,354. This is because the cost of the intervention remains the same, but the benefit is much reduced-by 10 years almost 40% of the people who had quit have restarted smoking. This means that they only have a temporary benefit of abstaining for a short period of time.
Discussion
We found that the state-transition and DES models reported similar results, but that varying long-term assumptions in the DES dramatically changed the results. Whilst costs and QALYs were not sensitive to model structure or utility decrements, they were sensitive to the inclusion of a longterm relapse rate. This is despite using different underlying approaches and sources for modelling comorbidities. To our knowledge, we are the first to directly compare state-transition and DES structures in smoking cessation. Claxton et al. [33] compared a patient-level simulation model with a cohort state-transition model in ophthalmology and found that the difference in results was relatively small using a simple patient-level simulation, but much greater using more sophisticated patient-level simulations. Claxton et al. [33] noted that patient-level simulations are better able to accurately represent the real world in ophthalmology. Simpson et al. [34] compared a DES with a state-transition model in HIV and found that the results were similar, and that the DES had better long-term predictive validity. Stevenson et al. [35] reviewed six economic models developed by manufacturers of biologics in rheumatoid arthritis, where three used DES, two used cohort-level state-transition models and one used an individual patient simulation model with fixed cycle lengths. The six models used similar data and assumptions and reported broadly similar results. In an independent analysis using a DES, Stevenson et al. [35] found that long-term assumptions about disease progression had a large influence on the cost-effectiveness results.
The DICE framework can be used to build state-transition or DES models, so in future, researchers could compare multiple model structures within one Microsoft Excel workbook. We show that where long-term treatment effectiveness and the downstream pathway does not vary between treatments, state-transition and DES models give comparable results and may be considered equally valid. State-transition models can make use of rich data sources such as Doll et al.'s study [28] reporting mortality by smoker status. On the other hand, a DES model would give the same results as a state-transition model for one line of treatment, so the structure is not expected to introduce bias when used for multiple lines or sequences of treatments.
We have demonstrated the feasibility of building a DES using readily available data, mostly using inputs that would be identified for a standard state-transition model. The DES did, however, require additional data sources for calculating inputs, such as for time since cessation and mortality risk by comorbidity. This increased the workload associated with developing the model, and increased the parameter uncertainty as more data sources were usedalthough we did strive to use recent, large, national datasets as far as available. The additional flexibility of the DES framework means that it could now be updated as data becomes available or as the decision problem develops, whereas adapting state-transition models to include additional health states or patient characteristics can be time consuming [5] . The flexibility of the DES means that it can use consistent data sources where available-for example, using utility data from Vogl et al. to consider the impact of smoker status and comorbidity from one dataset rather than combining from multiple sources which may not necessarily be valid.
The strengths and limitations of the DICE framework have been extensively discussed in the existing literature [6, 7] . One key limitation is the relatively slow execution of the DICE in Excel. Our model took around 20 min to generate results; while not prohibitively long, this is notably slower than state-transition models, which generate results instantaneously.
Caro reported that one of the advantages of the DICE framework is that as it uses a standard framework, only the disease-specific data needs to be validated each time. As our model has more events than either the sample model [6] or osteoporosis model [7] built using the DICE, there are more events tables and each has more conditions-validating each of these with experts may present a substantial undertaking. However, the use of counters within the DICE allows the model to report the proportion of people who experience each comorbidity, the age at death, and the number of quit attempts per person, which can be used to compare the modelled outcomes with the real world. (Additionally, the DICE can report each profile individually, such that reviewers can see each person's pathway through the model, although this increases the run time of the model.) In scenarios 1-4 for the DES, the average number of quit attempts per person is 1.44 for people receiving the intervention and 1.58 for people receiving no intervention. Everyone in the model makes one attempt at the start of the model, and then with an annual probability of 2% for a cohort aged 16 over a lifetime, most people make another attempt. Since the intervention has a higher probability of success than no treatment, fewer people in the intervention arm make further quitting attempts, and so the average number of quitting attempts is lower. In scenario 5, where long-term relapse is included, the number of average quit attempts per person is 2.27 for the intervention and 2.34 for no treatment. These are higher than scenarios 1-4 as people attempt quitting after they relapse so make more quit attempts. The number of quit attempts for intervention and no treatment is more similar as the effectiveness of the intervention is essentially reduced. Compared to the literature, all of these results for number of quit attempts are much lower than is observed in the real world, where evidence suggests people take between 6 and 30 attempts to quit before they are successful [36] . This suggests that models which consider only one intervention may not be valid and that future economic models in smoking cessation should include sequences of treatments to accurately estimate the cost-effectiveness of any additional intervention to current practice. The flexibility to include additional complexity and patient history are known advantages of DESs [5, 37] , which make them particularly well-suited to modelling sequences of treatments. Leaviss et al. noted that a DES would be needed to incorporate multiple quit attempts following relapse [29] . That said, if the sequence of subsequent treatments is identical between intervention and comparator, then a model may only need to capture the time period between the first quit attempts and relapse. However, the probability of successfully quitting on later treatments may depend on factors such as age and the number of and time since previous quit attempts [38] , which may then vary between the arms.
The main limitations of our current analysis lie within the data inputs used in the DES. Firstly, although the DES can link mortality to either smoker status or to comorbidity prevalence, neither approach is perfect. When mortality was linked to smoker status (in scenario 1), people with comorbidities did not have any reduction in life expectancy and so incurred high costs. In the state-transition model which links mortality to smoking status, using population prevalence adjusts for this by considering a relatively lower proportion of people with comorbidities in advanced age. Using incidence in the DES model does not do this, suggesting that the results and approach in this scenario may not be valid. Linking mortality to comorbidities may be more appropriate, but we considered only five comorbidities, and it is possible that other comorbidities may also impact on mortality, for example, through wound complications [39, 40] . It is possible that, individually, each additional comorbidity would have too small an impact on mortality to have been demonstrated in the literature, but cumulatively, the impact of several different comorbidities could have a meaningful clinical effect. By linking smoking status itself with mortality, this would be captured, whereas explicitly linking mortality to five comorbidities could underestimate the true effect. It should be noted that this is a limitation only of the DES scenarios considered here, and that a DES could link mortality to smoker status and comorbidity if appropriate data were available. Secondly, the use of empirical frequencies for incidence and death mean that the model can only sample the time to event to the nearest year, and looking up event probabilities from a table increases the model run time compared with sampling from a probability distribution. Thirdly, the information on long-term relapse and intervention effectiveness are from separate studies and do not necessarily consider identical patient populations. Despite this, we consider that our analyses provide a pragmatic comparison of two model structures. Our analysis indicates that smoking cessations may be less likely to be cost-effective when a longer pathway is modelled. Previously, most economic evaluations using 1-year quit rates as a proxy for longterm cessation have found individual smoking cessation interventions to be cost-effective [13] [14] [15] [16] [17] [18] [19] 29] . This is unsurprising when we consider the substantial health benefits and cost offsets gained by each individual quitter. However, if we were evaluating the addition of one intervention, with longterm relapse, to a pathway of treatments, then this may not be true. Therefore, it is important that the economic model captures the relevant pathway and that the positioning of a new intervention within the pathway is understood.
Conclusion
We have found that model structures themselves do not influence smoking cessation cost-effectiveness results, but that long-term assumptions do. Before building an economic model, developers should first consider the full treatment pathway in the decision problem. They should then develop a model to incorporate the long-term differences between treatment and comparator. The choice of model structure is only important inasmuch as it allows all relevant outcomes to be incorporated. Where state-transition models cannot capture repeated quit attempts or sequences of treatments that differ between arms, DES models are more appropriate.
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